Adaptimmune Therapeutics plc (NASDAQ:ADAP) Given Consensus Recommendation of "Hold" by Analysts

Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) has earned an average recommendation of "Hold" from the seven brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $1.52.

Several analysts recently commented on ADAP shares. Jones Trading lowered Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 11th. HC Wainwright cut their price objective on Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Barclays lowered their target price on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating on the stock in a report on Wednesday, May 14th. Wall Street Zen initiated coverage on shares of Adaptimmune Therapeutics in a research report on Friday, May 16th. They set a "buy" rating for the company. Finally, Wells Fargo & Company reduced their price target on shares of Adaptimmune Therapeutics from $1.50 to $1.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 14th.

Adaptimmune Therapeutics Price Performance

Shares of Adaptimmune Therapeutics stock traded down $0.00 during trading on Wednesday, hitting $0.28. 873,840 shares of the company's stock traded hands, compared to its average volume of 1,718,684. The company has a market cap of $75.01 million, a PE ratio of -1.29 and a beta of 2.24. The firm's fifty day moving average price is $0.27 and its 200 day moving average price is $0.45. Adaptimmune Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.48. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) EPS for the quarter, hitting analysts' consensus estimates of ($0.18). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The firm had revenue of $7.29 million during the quarter, compared to analysts' expectations of $6.55 million. Analysts forecast that Adaptimmune Therapeutics will post -0.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Two Sigma Investments LP lifted its position in shares of Adaptimmune Therapeutics by 33.5% during the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 19,146 shares in the last quarter. Virtu Financial LLC lifted its holdings in Adaptimmune Therapeutics by 21.5% during the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock worth $66,000 after buying an additional 21,688 shares in the last quarter. Invesco Ltd. lifted its holdings in Adaptimmune Therapeutics by 82.0% during the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock worth $34,000 after buying an additional 28,526 shares in the last quarter. Rock Springs Capital Management LP boosted its position in Adaptimmune Therapeutics by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock valued at $1,338,000 after buying an additional 58,000 shares during the last quarter. Finally, Two Sigma Advisers LP increased its stake in shares of Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after buying an additional 58,787 shares during the period. 31.37% of the stock is owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.